AI Article Synopsis

  • Hypercholesterolemia increases platelet aggregation, and this study assessed whether statins, specifically fluvastatin, can mitigate this effect and the underlying mechanisms involved.
  • Twelve hypercholesterolemic patients underwent a crossover trial comparing fluvastatin and colestimide, revealing that fluvastatin not only reduces cholesterol levels but also enhances platelet function by improving nitric oxide release and reducing harmful nitrotyrosine production.
  • Fluvastatin's ability to alter platelet aggregability occurs independently of cholesterol reduction, indicating additional beneficial effects on cardiovascular health beyond just lowering cholesterol levels.

Article Abstract

Background: Hypercholesterolemia enhances platelet aggregability. Statins have beneficial effects on cardiovascular events. The purpose of this study is to investigate whether statins inhibit platelet aggregation and, if so, the mechanisms.

Methods And Results: Twelve patients with hypercholesterolemia were prospectively randomized in a crossover design to receive either fluvastatin (20 mg/d) or colestimide (3000 mg/d) for 12 weeks. The subjects were switched to the opposite arm for additional 12 weeks. Before and after first and second treatments, experiments were performed. Eleven age-matched volunteers with normal lipid profiles served as controls. ADP-induced platelet aggregation, platelet-derive nitric oxide (PDNO) release, intraplatelet levels of GSH and GSSG, and intraplatelet nitrotyrosine production during platelet aggregation were measured. Fluvastatin and colestimide equally lowered total and low density lipoprotein cholesterol levels in hypercholesterolemia. Platelet aggregation was greater in hypercholesterolemia than in normocholesterolemia before treatment and was altered by fluvastatin. PDNO release, intraplatelet glutathione level, and GSH/GSSG ratio were lower in hypercholesterolemia than in normocholesterolemia before treatment and were increased by fluvastatin. Intraplatelet nitrotyrosine formation was greater in hypercholesterolemia than in normocholesterolemia, and decreased by fluvastatin. Colestimide did not have such effects. In vitro application of fluvastatin dose-dependently inhibited platelet aggregation. Furthermore, in vitro application of fluvastatin dose-dependently inhibited platelet nitrotyrosine expressions and the inhibitory effects by fluvastatin were reversed by preincubation with geranylgeranylpyrophosphate.

Conclusions: Fluvastatin altered platelet aggregability in hypercholesterolemic patients in a cholesterol-lowering independent manner, which was partly mediated by the improvement of intraplatelet redox imbalance.

Download full-text PDF

Source
http://dx.doi.org/10.1161/ATVBAHA.106.128793DOI Listing

Publication Analysis

Top Keywords

platelet aggregation
20
platelet aggregability
12
hypercholesterolemia normocholesterolemia
12
fluvastatin
10
platelet
9
patients hypercholesterolemia
8
improvement intraplatelet
8
intraplatelet redox
8
redox imbalance
8
pdno release
8

Similar Publications

Monitoring platelet aggregation is crucial for predicting thrombotic diseases and identifying the risk of bleeding or resistance to antiplatelet drugs. This study developed a microfluidic device to measure platelet activation with high sensitivity. By controlling exposure time through repeated reinjections, the device enables the detection of subtle changes in platelet activity influenced by lifestyle factors, such as alcohol consumption.

View Article and Find Full Text PDF

Impact of acetylsalicylic acid on perioperative bleeding complications in deceased donor kidney transplantation.

World J Urol

January 2025

Department of Urology, Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin, Humboldt-Universitaet zu Berlin, Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.

Purpose: The objective of this study was to evaluate the perioperative outcomes and complications associated with the use of acetylsalicylic acid (ASA) in deceased donor kidney transplantation (KTX), with a particular focus on bleeding events.

Methods: We retrospectively analyzed 157 kidney transplant recipients (KTRs) who underwent KTX at Charité Berlin, Department for Urology, between February 2014 and December 2017. Patients were divided into two groups: patients with ASA in their preoperative medication (Group A, n = 59) and patients without ASA use (Group B, n = 98).

View Article and Find Full Text PDF

Annexin A1: The dawn of ischemic stroke (Review).

Mol Med Rep

March 2025

Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan 450000, P.R. China.

Ischemic stroke is a prevalent clinical condition that poses a significant global challenge. Developing innovative strategies to address this issue is crucial. Annexin A1 (ANXA1), a key member of the annexin superfamily, performs various functions, such as inhibiting inflammatory factor release, promoting phagocytosis, and blocking leukocyte migration.

View Article and Find Full Text PDF

Background: Chalcones have been described in the literature as promising antineoplastic compounds.

Objectives: Therefore, the objective of this study was to analyze the cytotoxic effect of 23 synthetic chalcones on human acute leukemia (AL) cell lines (Jurkat and K562).

Methods: Cytotoxicity assessment was performed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method.

View Article and Find Full Text PDF

Germline variants of FLI1, essential for megakaryopoiesis, are linked to bleeding disorders, platelet aggregation defects and mild thrombocytopenia. However, the mechanisms behind these abnormalities remain unclear. This study aims to elucidate the impact of FLI1 variants on human megakaryocytes and platelets.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!